Merck said in a statement that it was working on ramping up production of the vaccine to be available in the third quarter of 2020. In the meantime, it will continue providing a version of the shot that was used in the trial.
The company hasn’t established a price for the drug. The drugmaker is working with Gavi, a nonprofit that provides support to global vaccine programs. The organization works throughout much of sub-Saharan Africa.
From the article: